Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MEGA MEDICAL TECHNOLOGY LIMITED

(formerly known as Wing Tai Investment Holdings Limited Ì) (Incorporated in Bermuda with limited liability)

(Stock Code: 876) (1) RETIREMENT AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS, MEMBERS OF AUDIT COMMITTEE AND NOMINATION COMMITTEE, CHAIRMAN AND MEMBER OF REMUNERATION COMMITTEE; AND (2) APPOINTMENT OF NON-EXECUTIVE DIRECTOR (1) RETIREMENT AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS

Reference is made to the circular (the "Circular") dated 27 May 2015 issued by Mega Medical Technology Limited (the "Company"). As stated in the Circular, as Mr. Zeng Zhaolin ("Mr. Zeng") and Mr. Lung Chee Ming George ("Mr. Lung") want to devote more time to their other business commitments, they did not offer themselves for re-election at the annual general meeting of the Company held on 26 June 2015 (the "AGM") and they retired as directors at the AGM. Upon their retirement, Mr. Zeng ceased to be the chairman of the remuneration committee (the "Remuneration Committee") of the Company and the members of the audit committee (the "Audit Committee") and the nomination committee (the "Nomination Committee") of the Company, and Mr. Lung ceased to be the members of the Remuneration Committee, the Audit Committee and the Nomination Committee.
Mr. Zeng and Mr. Lung have confirmed that they have no disagreement with the board of directors (the "Board") of the Company and there are no matters that need to be brought to the attention of the shareholders of the Company in relation to their retirement. The Board would like to take this opportunity to express its appreciation for Mr. Zeng's and Mr. Lung's contribution to the Company during their tenure of office.
The Board is pleased to announce, with effect from 27 June 2015, the appointment of (1) Mr. Wu Jixian as an independent non-executive director of the Company, the chairman of the Remuneration Committee and the member of the Audit Committee and the Nomination Committee and (2) Mr. Song Qun as an independent non-executive director of the Company and the member of the Remuneration Committee, the Audit Committee and the Nomination Committee.
- 1 -

Mr. Wu Jixian ("Mr. Wu")

Mr. Wu, aged 51, has over 20 years of working experience in, variously, trading, marketing and coal industry of the People's Republic of China (the "PRC"). Mr. Wu worked as the manager of Electric Appliance Export Division and the manager of Metallurgy & Mining Division of China National Machinery & Equipment Import & Export Shenzhen Co. Ltd. Mr. Wu had been an executive director and chief executive officer of Huscoke Resources Holdings Limited, a Hong Kong listed company, since June 2008 and had been re-designated to non-executive director in September 2011 until October 2014. Mr. Wu had also worked for certain overseas corporations, including the sales manager of JH Coal & Chemical International Inc., Canada, president of Marcell Industrial Inc., Canada and general manager of Great Launch Inc., Canada.
Mr. Wu entered into a service contract with effect from 27 June 2015 with the Company for a term of
2 years, and is subject to the provisions of retirement by rotation and re-election at the annual general meeting of the Company in accordance with the bye-laws of the Company. Pursuant to the service contract, Mr. Wu shall be entitled to a monthly remuneration of HK$15,000. The remuneration of Mr. Wu was determined with reference to the Company's remuneration policy, with regards to his duties and responsibility and the prevailing market condition.
Mr. Wu does not hold any position in the Company or its subsidiaries and saved as disclosed above, Mr. Wu did not hold any other directorship in any other public companies in Hong Kong or overseas in the last three years. Mr. Wu does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company or its subsidiaries (as defined by the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the "Listing Rules"). There is no other information that needs to be disclosed pursuant to any of requirement as set out in Rules 13.51(2) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company in connection with the appointment of Mr. Wu.
As at the date of this announcement, Mr. Wu does not have any interests in shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Mr. Song Qun ("Mr. Song")

Mr. Song, aged 49, currently acts as a finance strategy advisor for Tencent Technology (Shenzhen) Company Limited, a leading internet company, and the vice-chairman of Lefu Payment Company Limited, a leading third party payment company in the PRC. Mr. Song obtained a master degree of Business Administration from University of Melbourne and a bachelor degree in Engineering from Huazhong University of Science and Technology of the PRC. Mr. Song was formerly the president and chief executive officer of China Resources Bank. Prior to that he was the global head of Trust and Agency Services at HSBC. His working experience also included holding senior management positions in JP Morgan Chase and ANZ Bank.
Mr. Song entered into a service contract with effect from 27 June 2015 with the Company for a term of
2 years, and is subject to the provisions of retirement by rotation and re-election at the annual general meeting of the Company in accordance with the bye-laws of the Company. Pursuant to the service contract, Mr. Song shall be entitled to a monthly remuneration of HK$15,000. The remuneration of Mr. Song was determined with reference to the Company's remuneration policy, with regards to his duties and responsibility and the prevailing market condition.
- 2 -
Mr. Song does not hold any position in the Company or its subsidiaries and Mr. Song did not hold any other directorship in any other public companies in Hong Kong or overseas in the last three years. Mr. Song does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company or its subsidiaries (as defined by the Listing Rules). There is no other information that needs to be disclosed pursuant to any of requirement as set out in Rules 13.51(2) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company in connection with the appointment of Mr. Song.
As at the date of this announcement, Mr. Song does not have any interests in shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

(2) APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is also pleased to announce, with effect from 27 June 2015, the appointment of Dr. Jiang
Feng ("Dr. Jiang") as a non-executive director of the Company.
Dr. Jiang, aged 53, graduated from the Fourth Military Medical University with a bachelor degree of medicine in 1985, obtained an EMBA degree from Tsinghua University in 2007 and received a doctoral degree of clinical degree in 1995 from the Fourth Military Medical University. Dr. Jiang is currently standing vice president of China Association for Medical Devices Industry, chairman of China Strategic Alliance of Medical Devices Innovation, deputy director of Biomedical Engineering Education Steering Committee of the Ministry of Education, executive director of Chinese Society of Biomedical Engineering and Chinese Society for Biomaterials, researcher of Zhejiang University and director of Biomedical Technology Assessment Centre of Zhejiang University and president of the magazine China Medical Device Information. Dr. Jiang is formerly executive director of China Instrument and Control Society and chairman of its medical devices branch, and the executive director of China Association for Disaster & Emergency Rescue Medicine. Dr. Jiang has worked for 12 years as a clinician until 1997. In view of his outstanding achievements, Dr. Jiang was introduced as leaders of national scalable medicine and device companies, including as chairman and general manager of China National Pharmaceutical Group Corporation North West Company and China National Medical Equipment Co., Ltd for 9 years. Dr. Jiang has been the president and standing vice president of China Association for Medical Devices Industry, and the chairman of China Strategic Alliance of Medical Devices Innovation for 12 years and
5 years, respectively. Dr. Jiang is expert at the operation and management of medical companies and understands development trend in the industry.
Dr. Jiang is currently an independent non-executive director of Guangdong Biolight Meditech Co., Ltd. Grandhope Biotech Co., Ltd and Dirui Industrial Co., Ltd., all of which are listed on the Shenzhen Stock Exchange, and a non-executive director of Lifetech Scientific Corporation, a company being listed on the Stock Exchange. Dr. Jiang is formerly an independent non-executive director of Zhejiang Tiansong Medical Instrument Co. Ltd, a company listed on the Shenzhen Stock Exchange, until May 2015.
Dr. Jiang entered into a service contract with effect from 27 June 2015 with the Company for a term of
2 years, and is subject to the provisions of retirement by rotation and re-election at the annual general meeting of the Company in accordance with the bye-laws of the Company. Pursuant to the service contract, Dr. Jiang shall be entitled to a monthly remuneration of HK$15,000. The remuneration of Dr. Jiang was determined with reference to the Company's remuneration policy, with regards to his duties and responsibility and the prevailing market condition.
- 3 -
Dr. Jiang does not hold any position in the Company or its subsidiaries and saved as disclosed above, Dr. Jiang did not hold any other directorship in any other public companies in Hong Kong or overseas in the last three years. Dr. Jiang does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company or its subsidiaries (as defined by the Listing Rules). There is no other information that needs to be disclosed pursuant to any of requirement as set out in Rules 13.51(2) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company in connection with the appointment of Dr. Jiang.
As at the date of this announcement, Dr. Jiang does not have any interests in shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).
The Board would like to take this opportunity to welcome Mr. Wu, Mr. Song and Dr. Jiang to join the Board.
By order of the Board

Mega Medical Technology Limited Wen Jialong

Chairman and Executive Director

Hong Kong, 26 June 2015

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Wen Jialong (Chairman), Mr. Wu Xiaolin (Vice-Chairman) and Mr. Wu Tianyu (Chief Executive Officer), two non-executive Directors, namely Mr. Chow Tak Hung and Mr. Lam Kwok Cheong and one independent non-executive Director, namely Dr. Loke Yu alias Loke Hoi Lam.

- 4 -

distributed by